To our knowledge, currently, there is no combinational treatment consisting of TGF-β modulation with immunotherapy in TNBC models according to clinicaltrials.gov (accessed on 9 September 2021); however, there are trials consisting of galunisertib (LY2157299 monohydrate), a specific small-molecule inhibitor of TGF-βR1 kinase in combination with checkpoint inhibitors in NSCLC, HCC and pancreatic cancer patients (NCT02423343; NCT02734160) [84]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.